Here are four things to know:
1. Nine analysts rated the stock “buy,” 10 analysts rated it “outperform” and 10 analysts rated it “hold.”
2. Analysts gave a consensus estimate of $1.93 share, which compares with $1.58 the same quarter last year.
3. Wall Street analysts predict Zimmer Biomet will see an annual growth of about 10.69 percent over the next five years.
4. Some analysts predict the 12-month average price target will hit $150, while others predict it will reach $120.71.
More articles on devices:
Orthofix upgraded to ‘strong buy’ rating — 5 insights
MIS Pedicle Screw Systems receive additional clearance for larger diameter pedicle screws
5th Neuro-Spinal Scaffold for spinal cord injury shows improvement at 6 months: 5 key notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
